These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21048953)

  • 41. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).
    Baden LR; Walsh SR; Seaman MS; Tucker RP; Krause KH; Patel A; Johnson JA; Kleinjan J; Yanosick KE; Perry J; Zablowsky E; Abbink P; Peter L; Iampietro MJ; Cheung A; Pau MG; Weijtens M; Goudsmit J; Swann E; Wolff M; Loblein H; Dolin R; Barouch DH
    J Infect Dis; 2013 Jan; 207(2):240-7. PubMed ID: 23125444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W
    Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
    Fuchs JD; Bart PA; Frahm N; Morgan C; Gilbert PB; Kochar N; DeRosa SC; Tomaras GD; Wagner TM; Baden LR; Koblin BA; Rouphael NG; Kalams SA; Keefer MC; Goepfert PA; Sobieszczyk ME; Mayer KH; Swann E; Liao HX; Haynes BF; Graham BS; McElrath MJ;
    J AIDS Clin Res; 2015 May; 6(5):. PubMed ID: 26587311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
    Sedegah M; Tamminga C; McGrath S; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Manohar N; Richie NO; Wood C; Long CA; Regis D; Williams FT; Shi M; Chuang I; Spring M; Epstein JE; Mendoza-Silveiras J; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Soisson L; Diggs C; Carucci D; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2011; 6(10):e24586. PubMed ID: 22003383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
    Vardas E; Kaleebu P; Bekker LG; Hoosen A; Chomba E; Johnson PR; Anklesaria P; Birungi J; Barin B; Boaz M; Cox J; Lehrman J; Stevens G; Gilmour J; Tarragona T; Hayes P; Lowenbein S; Kizito E; Fast P; Heald AE; Schmidt C
    AIDS Res Hum Retroviruses; 2010 Aug; 26(8):933-42. PubMed ID: 20666584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
    Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
    J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.
    Stephenson KE; Keefer MC; Bunce CA; Frances D; Abbink P; Maxfield LF; Neubauer GH; Nkolola J; Peter L; Lane C; Park H; Verlinde C; Lombardo A; Yallop C; Havenga M; Fast P; Treanor J; Barouch DH
    PLoS One; 2018; 13(11):e0205139. PubMed ID: 30427829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
    Hayes P; Gilmour J; von Lieven A; Gill D; Clark L; Kopycinski J; Cheeseman H; Chung A; Alter G; Dally L; Zachariah D; Lombardo A; Ackland J; Sayeed E; Jackson A; Boffito M; Gazzard B; Fast PE; Cox JH; Laufer D
    Clin Vaccine Immunol; 2013 Mar; 20(3):397-408. PubMed ID: 23345581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
    Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
    J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
    Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
    J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
    Buchbinder SP; Mehrotra DV; Duerr A; Fitzgerald DW; Mogg R; Li D; Gilbert PB; Lama JR; Marmor M; Del Rio C; McElrath MJ; Casimiro DR; Gottesdiener KM; Chodakewitz JA; Corey L; Robertson MN;
    Lancet; 2008 Nov; 372(9653):1881-1893. PubMed ID: 19012954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
    Wecker M; Gilbert P; Russell N; Hural J; Allen M; Pensiero M; Chulay J; Chiu YL; Abdool Karim SS; Burke DS; ;
    Clin Vaccine Immunol; 2012 Oct; 19(10):1651-60. PubMed ID: 22914365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.
    Han Q; Williams WB; Saunders KO; Seaton KE; Wiehe KJ; Vandergrift N; Von Holle TA; Trama AM; Parks RJ; Luo K; Gurley TC; Kepler TB; Marshall DJ; Montefiori DC; Sutherland LL; Alam MS; Whitesides JF; Bowman CM; Permar SR; Graham BS; Mascola JR; Seed PC; Van Rompay KKA; Tomaras GD; Moody MA; Haynes BF
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
    Hartnell F; Brown A; Capone S; Kopycinski J; Bliss C; Makvandi-Nejad S; Swadling L; Ghaffari E; Cicconi P; Del Sorbo M; Sbrocchi R; Esposito I; Vassilev V; Marriott P; Gardiner CM; Bannan C; Bergin C; Hoffmann M; Turner B; Nicosia A; Folgori A; Hanke T; Barnes E; Dorrell L
    Front Immunol; 2018; 9():3175. PubMed ID: 30713538
    [No Abstract]   [Full Text] [Related]  

  • 58. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.
    Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E;
    Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
    Eller MA; Slike BM; Cox JH; Lesho E; Wang Z; Currier JR; Darden JM; Polonis VR; Vahey MT; Peel S; Robb ML; Michael NL; Marovich MA
    PLoS One; 2011; 6(9):e24254. PubMed ID: 21949699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
    Tamminga C; Sedegah M; Regis D; Chuang I; Epstein JE; Spring M; Mendoza-Silveiras J; McGrath S; Maiolatesi S; Reyes S; Steinbeiss V; Fedders C; Smith K; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Murphy J; Komisar J; Williams J; Shi M; Brambilla D; Manohar N; Richie NO; Wood C; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Diggs C; Soisson L; Carucci D; Levine G; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2011; 6(10):e25868. PubMed ID: 22003411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.